Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Accuray's Cancer Treatment Device CyberKnife To Expand In Japanese Market

This article was originally published in PharmAsia News

Executive Summary

With Japan's Ministry of Health, Labor and Welfare approval of CyberKnife, a cancer treatment device made by U.S. medical device maker Accuray in June, the device has been expanded from treating head and neck tumors to lung, liver, kidney, prostate and other cancers. Using image guidance technology and computer controlled robotics, the CyberKnife reduces necessary treatments from 50-70 times to only 5 times, and patients suffer less due to its painless nature and no need for anesthesia. Costing ¥600 million per unit, Accuray Japan President Mineo Kinashi said the company will apply for more insurance coverage for the treatment, and estimated that the market will increase from its current 20 units to 100 units in five years. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts